Scholarlink

<p>SARS-CoV-2 evolution toward antigenically distinct lineages drives escape from host immunity. JN.1 lineage derivatives have recently dominated the global epidemiologic landscape. In preclinical models, an LP.8.1-adapted BNT162b2 vaccine elicited higher serum neutralizing antibody responses against contemporary, circulating JN.1 sublineages, including the epidemiologically dominant XFG lineage, as compared to JN.1 and KP.2 vaccines. These findings supported the selection of an LP.8.1-adapted vaccine for the composition of the 2025-26 COVID-19 vaccine formula.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Preclinical immunogenicity of the LP.8.1-adapted BNT162b2 COVID-19 vaccine

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2026年7月6日

查看全文
  • Chaitanya Kurhade,
  • Wei Chen,
  • Weiqiang Li,
  • Kristin R. Tompkins,
  • Lyndsey T. Martinez,
  • Swati Rajput,
  • Emily Babiarz,
  • Aaron Yam,
  • Shin-Ae Lee,
  • Shikha Shrivastava,
  • Sarah O’Leary,
  • Subrata Saha,
  • Hui Yao,
  • Li Hao,
  • Todd Coffey,
  • Carla Iris Cadima Couto,
  • Alexander Muik,
  • Raquel Munoz Moreno,
  • Wesley Swanson,
  • Pilar Mendoza,
  • Uğur Şahin,
  • Annaliesa S. Anderson,
  • Kena A. Swanson,
  • Pirada Suphaphiphat Allen,
  • Kayvon Modjarrad

摘要

SARS-CoV-2 evolution toward antigenically distinct lineages drives escape from host immunity. JN.1 lineage derivatives have recently dominated the global epidemiologic landscape. In preclinical models, an LP.8.1-adapted BNT162b2 vaccine elicited higher serum neutralizing antibody responses against contemporary, circulating JN.1 sublineages, including the epidemiologically dominant XFG lineage, as compared to JN.1 and KP.2 vaccines. These findings supported the selection of an LP.8.1-adapted vaccine for the composition of the 2025-26 COVID-19 vaccine formula.